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Abstract
Background: There is scare information about HIV co-infections with hepatitis B virus (HBV) and/or hepatitis C virus
(HCV) among People Who Inject Drugs (PWID) in Mozambique. This information is critical to ensure the treatment
necessary to decrease the progression of liver disease and the transmission of both HIV and hepatitis. We assess the
prevalence of HIV, HBV and HCV co-infections as well as associated risk factors among PWID.
Methods: The first Bio-Behavioral Surveillance Survey was conducted in 2013–2014 among persons who self-
reported to have ever injected drugs. Using respondent-driven sampling, PWID aged 18 years and older were
recruited in two cross-sectional samples in Maputo and Nampula/Nacala, two large urban centers of Mozambique.
Rapid screening of HIV, HBV (HBsAg) and HCV was performed on site. Data from participants in both cities were
pooled to conduct RDS-weighted bivariate analyses with HIV/HBV and HIV/HCV co-infections as separate outcomes.
Unweighted bivariate and multivariate logistic regression analyses were conducted to assess correlates of co-
infection.
Results: Among 492 eligible PWID, 93.3% were male and median age was 32 years [IQR: 27–36]. HIV, HBV and HCV
prevalence were respectively 44.9% (95% CI:37.6–52.3), 32.8% (95% CI:26.3–39.5) and 38.3 (95% CI:30.6–45.9). Co-
infections of HIV/HBV, HIV/HCV and HIV/HBV/HCV were identified in 13.1% (95% CI:7.2–18.9), 29.5% (95% CI:22.2–
36.8) and 9.2% (95% CI:3.7–14.7) of PWID, respectively. Older age, history of needle/syringe sharing and history of
injection with used needle/syringe was associated with HIV/HBV co-infection. Living in Maputo city, have older age,
history of needle/syringe sharing and history of injection with used needle/syringe was associated with HIV/HCV co-
infection.
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Conclusion: There is a high burden of HBV and HCV among HIV-infected PWID in Mozambique. Our results
highlight the need for targeted harm reduction interventions that include needle exchange programs and
integrated services for the diagnosis and treatment of HIV, HBV and HCV to address these epidemics among PWID.
Efforts should be made to strengthen ART coverage in the population as an important treatment strategy for both
viruses.
Keywords: People who inject drugs, HIV, Hepatitis B, Hepatitis C, Co-infections, Respondent driven sampling,
Mozambique
Background
People who Inject Drugs (PWID) are among the most vul-
nerable to HIV infection, with an estimated prevalence of
17.8% globally and 8.3% in the Sub-Saharan African region
[1]. PWID are considered a key population for targeted
HIV prevention and treatment efforts due to their illicit
drug use and associated social stigma, which often makes
it difficult to obtain information about this population and
increases their vulnerability to HIV transmission [2, 3].
HIV ranks among one of the highest HIV prevalence
rates among adults aged 15–49 years old age (13.2%),
largely due to heterosexual transmission [4]. Although
the 3rd National HIV Strategic Plan recognized PWID
as a key population in 2010, there has been a lack of in-
formation about the population size, HIV prevalence
and their utilization of health services [5]. To address
this gap, the first Bio-Behavioral Surveillance (BBS) sur-
vey among PWID was conducted in two main urban cit-
ies between 2013 and 2014, using respondent-driven
sampling (RDS). This study estimated HIV prevalence at
50.1% in Maputo (95% CI: 40.1–59.0) and 19.9% in
Nampula/Nacala (95% CI: 10.9–29.2), where the greater
burden of HIV observed in the southern region is con-
sistent with the dynamics of the HIV epidemic in the
country [6, 7],.
In addition to HIV, viral hepatitis remains an important
global health issue, characterized by high prevalence, high
burden of morbidity and mortality, and suboptimal diag-
nosis and management approaches [8–10]. Viral hepatitis
are the most common viral infections affecting PWIDs
[10, 11]. HIV and viral hepatitis infections share common
transmission routes, risk behaviors and their co-infection
represents a serious global concern resulting in high mor-
bidity and mortality rates [11, 12]. HIV infection affects
the natural course of hepatitis B virus (HBV) and hepatitis
C virus (HCV), promoting faster progression to chronicity,
liver fibrosis, and malignancy [2, 9–11]. The BBS among
PWID in Mozambique estimated HBV prevalence at 32.1
and 36.4%, and HCV prevalence at 44.6 and 7.0%, in
Maputo and Nampula/Nacala respectively. Data about
HBV and HCV among the general population in
Mozambique is limited to a few studies in the southern re-
gion of the country [13, 14].
Global health targets to reduce HIV and viral hepatitis
infections have been established [15, 16]. Strengthening
the prevention and treatment of substance abuse, includ-
ing narcotic drug abuse, is listed as one of the priorities
of the United Nations 2030 Agenda for Sustainable De-
velopment Goals (Goal 3.5) [17]. Integrated harm reduc-
tion programs, in some countries have been designed to
address the assumption that the prevention of HIV in
PWID will also prevent hepatitis given their similar
modes of transmission and high-risk populations.
PWID have the highest burden of HIV among key
population groups in Mozambique and yet there con-
tinues to be lack of integrated prevention and treatment
services [18, 19]. In a country with one of the highest
HIV prevalence rates in the world, understanding the
epidemiology of HIV, HBV and HCV among PWID is
critical in order to design effective and efficient preven-
tion and treatment programs. Neglecting to implement
targeted services has the potential to compromise the
success of the overall HIV response in the country.
As such, the objective of this secondary analysis was to
evaluate HIV/HBV and HIV/HCV co-infections among
PWID in Mozambique and to assess associated risk fac-
tors. The findings from this paper emphasize the im-
portance of focusing on the dynamics of this population
and could also support the current drafting of the Na-
tional Harm Reduction Plan. The population has the
highest burden of HIV among key population groups
and yet there continues to be lack of integrated services
for HIV and viral hepatitis. Since Mozambique has one
of the highest HIV prevalence rates in the world,
neglecting to implement targeted services has the poten-
tial to compromise the success of HIV prevention and
control programs in the country. The findings from this
paper emphasize the importance of focusing on the dy-
namics of this population and could also support the
current drafting of the National Harm Reduction Plan.
Methods
Study design, target population, recruitment, and
sampling
We conducted a cross-sectional survey using RDS sam-
pling methodology in the two urban cities of Maputo
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and Nampula/Nacala, located in the South and North
regions of Mozambique, respectively. This survey meth-
odology has been widely used among hard-to-reach pop-
ulations to estimate HIV prevalence and associated risk
factors, and also to evaluate access and use of health ser-
vices [6, 7, 20–25]. Recruitment occurred between Sep-
tember 2013 and March 2014. The recruitment
procedures have been published previously [6, 7].
Participants were be eligible for inclusion in the study,
if they were at least 18 years of age; lived, worked or so-
cialized in the survey area within the last 12 months;
injected drugs without a medical prescription within the
last 12 months (in December 2013, eligibility require-
ments were expanded to anyone who had ever injected
drugs at any point in their lives to overcome recruitment
challenges). They also needed to be in possession of a
valid recruitment coupon and have and mental ability to
provide written informed consent. Participants received
a prevention and hygiene kit, 50 MZN (~$2.50) in cash
to compensate for transportation costs, and 50 MZN
worth of mobile phone credit for every successfully re-
ferred peer who participated in the survey.
A behavioral questionnaire was administered, and
blood sample collected for on-site rapid tests for HIV,
HBV and HCV. The HIV rapid testing procedures ad-
hered to the national algorithm using Determine™ HIV-
1/2 (Alere, USA), followed by a confirmatory test using
Uni-Gold HIV™ (Trinity Biotech, Ireland). The results of
the rapid HIV tests, together with self-reported prior
HIV-positive test results, were used to estimate HIV
prevalence. On-site rapid HBV testing was done using
Alere Determine® HbsAg (Abbott Laboratories, UK), to
detect surface antigen, and HCV testing used SD Bioline
HCV (Standard Diagnostics, Korea). Participants with
reactive HbsAg results or HCV antibodies were consid-
ered as having an active HBV and HCV infection, re-
spectively; none of the tests were able to determine if
infection was acute or chronic. Participants with positive
results for any of the laboratory tests were referred to a
nearby health facility, identified during the formative as-
sessment, where trained teams were ready to link them
to treatment services [6, 7].
Dried Blood Spot (DBS) were also collected and ana-
lyzed at the central laboratory of the National Institute
of Health. Central-level HBV tests were performed at
the National Institute of Health Laboratory using ELISA
Murex® HBsAg Version 3 (Murex Biotech Limited, UK)
and were used to estimate HBV prevalence in the survey;
centralized HCV testing was not performed because a
serologic anti-HCV assay using DBS had not been vali-
dated by the National Reference Laboratory at the time
of the survey [6, 7].
Separate informed consent was required for behavioral
questionnaire and each separate laboratory test; 47
participants did not consent to rapid HIV testing, two
participants did not consent for HBV, and 46 partici-
pants did not consent to HCV testing.
Behavioral indicators
Demographic information and self-reported sexual and
injection risk behaviors were recorded through face-to-
face interviews using a structured questionnaire deliv-
ered by trained interviewers. The network size was
assessed by asking: “Approximately how many people
who inject drugs do you think live in and around the city
of <Maputo or Nampula>?”
Statistical analysis
For the purpose of this analysis, data on survey partici-
pants from both cities were pooled given the low sample
size. RDS-adjusted pooled descriptive statistics were
used to describe participants demographic characteris-
tics, drug use behaviors, HIV/HBV, HIV/HCV, HIV/
HBV/HCV co-infections, as well as singular infections.
Site level analysis of these variables were adjusted for the
sampling method where the adjustment takes into con-
sideration the probability of each participants inclusion
in the study based on their self-reported network size.
Pooled estimates were weighted by the size of the PWID
population in each study site, based on four approaches
to produce estimates of the PWID population size in
each city. The median of the four estimates in each site
resulted in a PWID population size of 1684 in Maputo
and 520 in Nampula. These RDS-adjusted pooled preva-
lence estimates and 95% confidence intervals (CI) were
obtained using the aggregate estimate feature within the
RDS Analyst suite of tools [26].
Unadjusted pooled bivariate and multivariable logistic
regression analyses were conducted to identify correlates
for the two outcomes of interest: HIV/HBV and HIV/
HCV. Correlates included in the final model were se-
lected based on literature review and the results of the
bivariate association (p < 0.05) with the outcomes of
interest. This analysis was conducted using R Statistical
Software v.3.1.1 (r Development Core Team, Vienna,
Austria).
Ethical considerations
This is a secondary data analysis from a survey protocol
that was approved by the Mozambican National Bioeth-
ics Committee for Health (CNBS) (46/CNBS/13) and the
Institutional Review Board of the University of California
at San Francisco (13–10,699); the US Centers for Disease
Control and Prevention (CDC) determined the protocol
to be research where CDC was not engaged. Participants
provided informed consent for study participation and
no personal identifying information was collected.
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Table 1 People who Inject Drugs population description in two urban settings in Mozambique, 2013–2014 (N = 492)
Characteristics PWID Study Population
n % unweighted RDS-weighted % (95%CI)
City
Maputo 353 71.7 –
Nampula/Nacala 139 28.3 –
Crude median age (years) [IQR]a 32 [27–36]
Age group (years)
18–24 92 18.7 18.2 (1.3–23.3)
≥ 25 400 81.3 81.8 (76.7–86.8)
Gender
Male 467 94.9 93.3 (90.3–96.3)
Female 25 5.1 6.7 (3.6–9.7)
Marital status
Single/never married 289 58.7 60.9 (55.6–66.3)
Cohabitating/married 103 20.9 20.5 (13.9–26.9)
Widowed/divorced/separated 100 20.3 18.6 (13.1–24.1)
Education
No formal education/primary 210 42.8 50.1 (44.0–57.2)
Secondary/higher 281 57.2 49.9 (42.8–55.9)
Religion
Christian (catholic, evangelical, protestant) 247 50.2 54.8 (48.3–61.3)
Muslim 143 29.1 25.5 (19.5–31.5)
Other/None 102 20.7 19.7 (14.4–24.9)
Age of first drug use (years)
< 18 56 11.7 7.9 (0.1–14.9)
18–24 235 49.1 50.9 (45.8–55.9)
≥25 188 39.2 41.2 (34.5–47.8)
No of sexual partners, last 12 months, males only (N = 456)b
0 94 20.6 19.9 (15.5–24.3)
1 95 20.8 24.2 (19.0–29.4)
≥2 267 58.6 55.9 (49.6–62.1)
Frequency of drug injection in the last 12months
Did not use 25 5.1 7.9 (4.5–11.8)
Few times per year or month 192 39.0 40.0 (34.0–46.1)
Daily 275 55.9 51.9 (45.4–58.4)
Had access to new syringes in the past 12months (N = 491) 425 86.6 87.3 (82.6–92.1)
Ever shared needles or syringes 258 52.4 48.8 (42.1–55.6)
Shared syringes in the last month 146 29.7 27.2 (20.5–33.8)
Ever injected with a previously used needle/syringe (N = 491) 391 79.6 74.8 (68.6–81.1)
Ever shared any other injection equipment c 158 32.1 33.6 (26.9–40.4)
Had unprotected sexual intercourse at last sex (N = 491)
Yes 214 43.6 44.3 (37.6–51.0)
No, used a condom 173 35.2 36.1 (30.2–42.0)
Not sexually active 104 21.2 19.4 (13.1–25.8)
Received condoms in the past 12 months (N = 489) 188 38.4 34.6 (28.6–40.6)
Ever incarcerated 328 66.7 64.3 (58.2–70.6)
a IQR Interquartile range
b 11 male subjects did not report number of sexual partners
c Other includes spoon, cotton or cleaning agent
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Results
Population characteristics
A total of 353 PWID were enrolled in the survey in
Maputo and 139 in Nampula/Nacala. When pooling re-
sults, the majority of participants were male (93.3,
95%CI: 90.3–96.3), and the median age was 32 years.
Half (49.9, 95%CI: 42.8–55.9) had completed secondary
or higher education. The majority of participants were
Christian (54.8, 95%CI: 48.3–61.3) and were single or
never married (60.9, 95%CI: 55.6–66.3). Table 1 presents
the RDS-Adjusted characteristics of the survey
participants.
About half the participants (50.9, 95% CI: 45.8–55.9)
reported initiation of injection drug use when they were
between the ages of 18–24 years and reported daily drug
injection during the past year (51.9, 95%CI: 45.4–58.4).
Although 87.3% (95%CI: 82.6–92.1) of participants
stated that they had access to brand new syringes, shar-
ing was a common practice and 48.8% (95%CI: 42.1–
55.6) of participants reported having shared a needle or
syringe at least once in their lifetime, while a quarter
(27.2, 95%CI: 20.5–33.8) reported sharing in the month
prior to the survey. Nearly two-thirds of participants
(64.3, 95%CI: 58.2–70.6) reported that they have ever
been incarcerated (Table 1).
Prevalence of HIV, HBV, HCV and co-infections
As presented in Table 2, HIV prevalence among partici-
pants was 44.9% (95% CI: 37.6–52.3). The prevalence of
HBsAg among PWID was 32.8% (95%CI: 26.3–39.5) and
38.3% for hepatitis C virus antibody (95%CI: 30.6–45.9).
Co-infection of HIV/HBV was found in 13.1% (95%CI:
7.2–18.9), and HIV/HCV co-infection was found in
29.5% (95%CI: 22.2–36.8) of PWID. Triple infection of
HIV/HBV/HCV was identified in 9.2% (95%CI: 3.7–14.7)
of PWID.
Associated risk factors for HIV/HBV and HIV/HCV co-
infection
In multivariate analysis, older age (aOR 12.9, 95%CI:
3.6–233.5), ever shared needles/syringes (aOR 1.8,
95%CI: 1.2–3.4) and ever injected with a previously used
needle/syringe (aOR 5.3, 95%CI: 1.9–22.4) was associ-
ated with HIV/HBV co-infection (Table 3). Living in
Maputo (aOR 4.4, 95%CI: 2.0–11.1), older age (aOR
22.8, 95% CI: 4.6–414.6), ever sharing needles or syrin-
ges (aOR 4.0, 95%CI 2.1–7.7), ever injecting with a pre-
viously used needle/syringe (aOR 12.1, 95%CI: 4.1–46.3)
were associated with HIV/HCV co-infection (Table 4).
Discussion
Our data indicates that approximately one-third of
PWID participants have serological evidence of HIV
(44.9%), HBV (32.8%) or HCV (38.3%), which is substan-
tially higher than prevalence rates estimated for PWID
reported from sub-Saharan African region for the three
infections at 18.3, 3.7, 21.8%, respectively [1].
Our prevalence of HIV/HBV co-infection (13.1%)
fall within the range observed in a previous study in
the sub-Saharan region (0–28.4%) [27]. The HIV/
HBV co-infection estimate is higher than that among
other population groups in the Mozambique where
there was an estimated 4.9% of youths HIV infected
in Maputo [13] and 9.1% of untreated HIV-infected
adults [14]. The hepatitis B vaccine was only intro-
duced into the Mozambican national vaccine pro-
gram for children in 2001 [28]. Although the HBV
vaccine is not widely available for the adult popula-
tion, anti-retroviral therapy (ART) based-on tenofo-
vir (TDF), lamivudine (3TC) and efavirenz (EFV) has
dual treatment benefits for both HBV and HIV in-
fections [9, 12, 27].
The prevalence of HIV/HCV co-infection among
PWID participants found in this study (29.5%) was sub-
stantially higher than the estimated prevalence in the
sub-Saharan region (5.7%). Only a few studies have in-
vestigated HIV/HCV co-infection among PWID in the
sub-Saharan region, and there is no previous empirical
estimation HIV/HCV co-infection in Mozambique. Des-
pite the lack information, there is clear evidence that
HIV is associated with a higher risk of infection with
HCV due to the similar mode of transmission though in-
fected blood [29, 30].
Table 2 Prevalence of HIV, hepatitis and co-infections in PWID in two urban settings in Mozambique, 2013–2014
Characteristics PWID Study Population
n % unweighted RDS-weighted % (95%CI)
HIV infected (N = 445a) 204 45.8 44.9 (37.6–52.3)
HBV infected (N = 490a) 164 33.5 32.8 (26.3–39.5)
HCV infected (N = 446a) 163 36.5 38.3 (30.6–45.9)
HIV/HBV co-infection (N = 444a) 59 13.3 13.1 (7.2–18.9)
HIV/HCV co-infection (N = 424a) 124 29.2 29.5 (22.2–36.8)
HIV/HBV/HCV co-infection (N = 423a) 40 9.5 9.2 (3.7–14.7)
a Denominator reflects the number of participants who consented to testing for each biomarker
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Table 3 Predictors of HIV/HBV co-infection among PWID study participants, 2013–2014 (N = 442)
Characteristics n/N Prevalence of HBV/HIV Crude OR 95% CI p-value aOR 95% CI p-value
City
Maputo 49/318 15.1 2.1 0.9–3.9 0.01 1.5 0.7–3.4 0.27
Nampula/Nacala 10/126 7.9 1
Age group (years)
18–24 1/83 1.2 1
≥25 58/361 16.1 15.7 3.4–279.5 < 0.01 12.9 2.6–233.5 < 0.01
Gender
Male 56/424 13.2 0.9 0.3–3.8 0.17 – – –
Female 3/20 15.0 1
Marital status
Single/never married 33/260 12.7 0.8 0.4–1.6 0.52 – – –
Cohabitating/married 12/93 12.9 0.8 0.3–1.8 0.63 – – –
Widowed/divorced/separated 14/91 15.4 1
Education level
No formal education/Primary school 22/189 11.6 0.7 0.4–1.3 0.37 – – –
Secondary/Higher 37/254 14.6 1
Age at first drug use (years)
< 18 6/50 12.0 1
18–24 29/213 13.6 1.2 0.4–3.2 0.76 – – –
≥25 22/169 13.0 1.1 0.4–3.1 0.85
No of sexual partners, last 12months
0 10/89 11.2 1
1 11/85 12.9 1.7 0.4–2.9 0.73 – – –
≥2 35/239 14.6 1.3 0.6–3.0 0.43 – – –
Gave money, good goods or services in exchange for sex in the, past 12monthsa
Yes 19/182 10.4 0.6 0.3–1.1 0.10 – – –
No 37/231 16.0 1
Received money, goods or services in exchange for sex, past 12months
Yes 7/73 9.6 0.6 0.3–1.3 0.27 – – –
No 49/340 14.4 1
Ever received drugs in exchange for sex, lifetime
Yes 10/59 16.9 1.3 0.6–2.8 0.38 – – –
No 49/384 12.8 1
Had unprotected sexual intercourse at last sex
Yes 22/196 11.2 1.0 0.47–2.2 0.18 – – –
No, used a condom 26/149 15.0 1.7 0.08–3.7 1.01 – – –
Not sexually active 11/98 1
Frequency of drug use, last 12months
Did not use 1/22 4.3 1
Daily 38/249 15.3 3.9 0.7–71.9 0.18 – – –
Few times per year/month week 20/172 11.6 2.8 0.6–53.2 0.31 – – –
Ever shared needles/syringes
Yes 42/244 17.2 2.2 1.3–4.2 < 0.01 1.8 1.2–3.4 0.05
No 17/200 8.5 1
Semá Baltazar et al. BMC Public Health          (2020) 20:851 Page 6 of 11
In this study, we found that the prevalence of HIV/
HBV and HIV/HCV co-infection among PWID in-
creased with age. Several studies demonstrated that
co-infection with HBV or HCV increase with age
among HIV-infected individuals [31, 32]. Because HIV
and viral hepatitis are chronic and sometimes asymp-
tomatic infections, it is likely that individuals are at
an even higher risk of progression to chronicity given
the combined effects of age and related immune sys-
tem dysfunction [33].
Our study also showed that PWID who re-used nee-
dle/syringe after someone had injected were almost five
and 12 times as likely to be co-infected with HIV/HBV
and HIV/HCV, respectively. Other studies have found
that HIV and hepatitis transmission are associated with
high-risk injection practices such as injection with a syr-
inge previously used by another PWID [2, 9, 10, 30, 34].
Individuals living with HIV/HCV co-infection are less
likely to clear acute HCV infection and more likely to
transmit the virus which is particularly of concern for
PWID who may be sharing used needles [35].
Despite overwhelming evidence of the effectiveness of
harm reduction for preventing the spread of HIV and re-
ducing other health issues associated with drug use, glo-
bal harm reduction service coverage remains insufficient
[36]. Mozambique does not have integrated harm reduc-
tion programs and policies to reduce the high-risk sexual
and drug use behaviors that contribute to the growing
HIV epidemic in the country [18]. In 2018, the first
drop-in center for people who use drugs was opened as
a demonstration site in Maputo to provide comprehen-
sive medical care for people who use drugs before link-
age to more comprehensive healthcare services. Clients
receive point-of-care screening for HIV, hepatitis, syph-
ilis, tuberculosis and referrals for clinical care as needed
[37]. However, so far, the services are restricted to one
urban location in the country.
A comprehensive harm reduction package needs to be
adopted and should include access to new needle and
syringe; opioid substitution therapy (OST); HIV services
(including HIV prevention counseling, testing an ART);
prevention and treatment of STIs; prevention, diagnosis
and treatment of TB and viral hepatitis (B and C), risk
reduction information and education for PWID and
their sex partners, and condom distribution programmes
for PWID and their sex partners [38–40]. Some coun-
tries have adopted an integrated harm reduction package
to prevent both HIV and hepatitis infection among
PWID, given their similar mode of transmission via sex-
ual exposure and high-burden of infection in specific
populations [9, 36, 41]. Efforts to promote condom use
must specifically address PWID in an environment free
to stigma and discrimination [42].
Although this represents the first analysis of HIV a
viral hepatitis among PWID in Mozambique, some limi-
tations should be considered. Given the low sample size,
Table 3 Predictors of HIV/HBV co-infection among PWID study participants, 2013–2014 (N = 442) (Continued)
Characteristics n/N Prevalence of HBV/HIV Crude OR 95% CI p-value aOR 95% CI p-value
Shared needles/syringes in the last month
Yes 22/138 15.9 1.3 0.7–2.4 0.27 – – –
No 37/306 12.1 1
Ever injected with a previous used needle/syringe
Yes 56/358 15.6 5.0 1.8–21.1 < 0.01 5.3 1.9–22.4 0.01
No 3/85 3.5 1
Ever shared any other injection equipmentb
Yes 18/146 12.3 0.8 0.4–1.5 0.64 – – –
No 35/250 14.0 1
Had access to new syringes in the past 12months
Yes 51/382 13.4 1
No 7/61 11.5 0.8 0.3–1.8 0.68 – – –
Received condoms in the past 12months
Yes 27/172 15.7 1
No 32/269 11.9 0.7 0.4–1.2 0.25 – – –
Ever incarcerated
Yes 45/296 15.2 1.7 0.9–3.3 0.09 1.2 0.6–2.4 0.63
No 14/148 9.5 1
a Excluded female participants
b Other includes spoon, cotton or cleaning agent
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Table 4 Correlates of HIV/HCV co-infections among PWID study participants, 2013–2014 (N = 422)
Characteristics n/N Prevalence of HCV/HIV OR 95%CI p-value aOR 95% CI p-value
City
Maputo 8/124 38.7 9.1 4.6–20.9 < 0.01 4.4 2.0–11.1 < 0.01
Nampula/Nacala 116/300 6.5 REF
Age group (years)
18–24 2/80 2.5 1
≥25 122/344 35.5 21.4 6.5–131.6 < 0.01 22.8 4.6–414.6 < 0.01
Gender
Male 119/408 29.2 0.9 0.3–2.9 0.86 – – –
Female 5/16 31.2 1
Marital status
Single/never married 73/249 29.3 0.6 0.3–1.1 0.12 0.72 0.4–1.4 0.38
Cohabitating/married 18/89 20.2 0.4 0.2–0.8 < 0.01 1.3 0.7–2.6 0.32
Widowed/divorced/separated 33/86 38.4 1
Education level
No formal education/Primary school 57/177 32.2 1.2 0.8–1.9 0.27 – – –
Secondary/Higher 67/246 27.2 1
Age of first drug use
< 18 12/49 24.5 1
18–24 57/202 28.2 1.2 0.6–2.5 0.60 – – –
≥25 51/161 31.7 1.4 0.7–3.0 0.34 – – –
No of sexual partners, last 12months
0 27/85 31.8 1
1 23/83 27.7 0.8 0.4–1.5 0.56 – – –
≥2 68/231 29.4 0.9 0.5–1.5 0.68 – – –
Gave money, good or services in exchange for sex in the, last 12monthsa
Yes 44/176 25.0 0.6 0.4–1.0 0.07 – – –
No 74/223 33.2 1
Received money, goods or services in exchange for sex, last 12months
Yes 15/70 21.4 0.6 0.3–1.1 0.10 – – –
No 103/329 31.3 REF
Ever received drugs in exchange for sex, lifetime
Yes 16/57 28.1 0.9 0.4–1.7 0.82 – – –
No 108/366 29.5 1
Had unprotected sexual intercourse at last sex
Yes 38/191 19.9 0.55 0.3–1.0 < 0.05 – – –
No, used a condom 86/233 36.9 1.6 0.9–2.7 1.12 – – –
Not sexually active REF
Frequency of drug use, last 12months
Did not use 1/22 43.2 1
Daily 102/236 12.7 15.9 3.3–288.9 < 0.01 – – –
Few times per year/month week 21/145 14.5 3.0 0.5–55.9 0.29 – – –
Ever shared needles or syringes
Yes 96/236 40.7 3.9 2.5–6.4 < 0.01 4.0 2.1–7.7 < 0.01
No 28/188 14.9 1
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this secondary analysis pooled results from the two sur-
vey cities resulting in the loss of social networks and
chains. As such, these results should be interpreted with
caution when generalizing to the full PWID population
in these cities. Also, there was a change in recruitment
criteria during the survey, to include individuals who
ever injected drugs without a prescription, which may
have resulted in including participants with lower recent
risk of HIV and hepatitis infection. However, since most
participants reported having injected during the last
month prior to the survey, the change in inclusion cri-
teria may not have had a significant influence. As is the
case with all cross-sectional surveys, self-reported data
could be subject to recall bias and/or social desirability
bias and it is also difficult to assess causality. Finally,
many participants refused to have the HCV test (9.4% of
the sample), perhaps due an absence of point-of-care
testing or treatment options within the national health
care system at the time of survey implementation, which
may underestimate the true prevalence of HCV in the
population.
Conclusions
This was the first analysis to evaluate the epidemio-
logical profile and risk factors for HIV/HBV and HIV/
HBC co-infections among participants in the PWID BBS
survey in Mozambique. The high burden of disease
among this population requires a enhance public health
interventions since HIV and viral hepatitis co-infection
increases morbidity and mortality, as well changes the
natural history of all infections. An integrated harm re-
duction strategy is necessary to address all infections
simultaneously. These services must be enhanced at
health facilities but implementation must also be decen-
tralized through community-based outreach, drop-in
centres and special environments, such as prison set-
tings. Further investigation should assess the feasibility
of introducing HBV vaccination in this high-risk popula-
tion within the Mozambican context, as an important
strategy prevent associated co-morbidities and improve
their overall health status.
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